Coeptis Therapeutics - רווח למניה בשנים עשר החודשים האחרונים COEP

Coeptis Therapeutics (COEP) brings together leading oncologists to develop innovative cell therapies. The absence of commercial products results in a capital burn without operating revenue. Given strict FDA oversight and a limited R&D pipeline, the current EPS TTM helps assess the fundamental basis, while the -2.79 metric determines this level on the chart.
COEP (Coeptis Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator is calculated by dividing the total net income over the last four quarters by the number of shares outstanding. This metric allows for an assessment of the actual return per security, excluding market noise. For Coeptis Therapeutics (COEP), the negative trend in the annual earnings per share TTM reflects high R&D costs in the absence of commercial sales. Rising operating expenses during the early stages of blood cancer therapy trials are increasing the fundamental loss. Analyzing the annual earnings per share TTM helps investors avoid overpaying for an asset with negative cash flow.